Loading...

KROS KEROS THERAPEUTICS INC Product Launches 8-K Filing

KRS

KRS

KEROS THERAPEUTICS INC

(KROS)

2025 8-K

Show Summary

Show Summary

Management Changes

Financial Statements

Board Nominations

Clinical Trial Results

Bylaw Amendments

Conference Participation

Financial Results

Conference Announcement

License Agreement

Corporate Update

Trial Dosing Halt

Clinical Trial Update

License Agreement

Conference Participation

Quarterly Results

Conference Announcement

Management Change

Trial Enrollment Update

TROPOS Trial Update

Conference Participation

Presentation Update

Earnings Reports

Sales Agreement

Transition of Executives

Clinical Trial Results

Investor Conferences

Annual Meeting of Stockholders

Appointment of Director

Earnings Reports

FDA Fast Track Designation ...

Presentation Update

Resignation of Chief Medica...

Financial Results Announcement

Public Offering

Underwriting Agreement

Corporate Presentation and ...

Additional Data from Phase ...

Announcement of CEO Partici...

Regulation FD Disclosure

Results of Operations and F...

Presentation Update

Earnings Reports

Investor meetings

Clinical Trial Data Announc...

Conference Presentation

Annual Meeting of Stockholders

Financial Results Announcement

Appointment of Director

Earnings Report

Regulation FD Disclosure

Regulation FD Disclosure

Lease Amendment

External Links:

On March 31, 2025, Keros Therapeutics announced initial topline results from the Phase 1 clinical trial of KER-065 in healthy volunteers, with a conference call scheduled for the same day to discuss these results.

AI Assistant

KEROS THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.